| __timestamp | CRISPR Therapeutics AG | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 205018000 |
| Thursday, January 1, 2015 | 12573000 | 392709000 |
| Friday, January 1, 2016 | 42238000 | 299694000 |
| Sunday, January 1, 2017 | 69800000 | 397061000 |
| Monday, January 1, 2018 | 113773000 | 434100000 |
| Tuesday, January 1, 2019 | 179362000 | 782200000 |
| Wednesday, January 1, 2020 | 269407000 | 1119900000 |
| Friday, January 1, 2021 | 17953000 | 2437500000 |
| Saturday, January 1, 2022 | 110250000 | 1560400000 |
| Sunday, January 1, 2023 | 130250000 | 1815800000 |
| Monday, January 1, 2024 | -2314000 | 1970500000 |
Cracking the code
In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. Regeneron Pharmaceuticals, Inc. and CRISPR Therapeutics AG, two titans in the field, showcase intriguing expense trends over the past decade. From 2014 to 2023, Regeneron consistently outpaced CRISPR in cost of revenue, with figures peaking at approximately $1.82 billion in 2023, a staggering 785% increase from 2014. In contrast, CRISPR's cost of revenue grew from a modest $1.5 million in 2014 to around $130 million in 2023, marking an exponential rise of over 8,500%.
Regeneron's costs surged notably in 2021, reaching $2.44 billion, reflecting its expansive growth and investment in innovation. Meanwhile, CRISPR's costs, though smaller in absolute terms, highlight its rapid scaling and increasing market presence. These trends underscore the dynamic nature of biotech expenses, driven by research, development, and market expansion.
Cost of Revenue Trends: Eli Lilly and Company vs CRISPR Therapeutics AG
Cost Insights: Breaking Down AstraZeneca PLC and CRISPR Therapeutics AG's Expenses
Cost Insights: Breaking Down Amgen Inc. and Regeneron Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Walgreens Boots Alliance, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Alkermes plc
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Evotec SE's Expenses
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Trends: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: CRISPR Therapeutics AG vs Mesoblast Limited